According to Nouryon, its chromatography media, a key product in the company's Consumer & Life Sciences segment, are used for purifying novel peptide-based pharmaceuticals, including treatments for type 2 diabetes and obesity.

“The rapidly growing demand for peptide-based drugs, driven by the rising prevalence of diabetes and obesity, requires a robust and reliable supply chain to ensure that patients around the world have access to the medications they need to lead healthier lives,” said Larry Ryan, president at Nouryon.

Suzanne Carroll, senior vice president of Consumer & Life Sciences at Nouryon, commented: “This expansion will enable us to continue as a leading supplier of high-quality silica-based chromatography media for active pharma ingredients.”